NASDAQ · ALT
Altimmune, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ALT: Nov 5, 2026
Altimmune, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.14. The reported EPS for the same quarter last year was $-0.21.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.14 | $-0.13 | $-0.15 | 4 |
| Dec 2026 | $-0.16 | $-0.14 | $-0.20 | 4 |
| Mar 2027 | $-0.17 | $-0.15 | $-0.18 | 2 |
| Jun 2027 | $-0.17 | $-0.15 | $-0.18 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · Zacks · MarketBeat · RTTNews- Fintel · Oct 29, 12:13 PM EDTAltimmune, Inc. Draws $10.0 million Tranche Three Under Loan AgreementOn October 27, 2026, Altimmune, Inc. drew $10.0 million in an aggregate principal amount, designated as Tranche Three, from its $125.0 million Loan and Security Agreement. The Loan and Security Agreement, dated as of May 13, 2025, and amended by the Amendment to Loan and Security
- Fintel · Oct 27, 11:58 AM EDTAltimmune, Inc. Appoints Peter Greenleaf and Alex Howarth to Board of DirectorsOn October 23, 2026, the Board of Directors of Altimmune, Inc. appointed Peter Greenleaf and Alex Howarth as directors of the Board effective November 2, 2026, and approved an increase in its size from nine to eleven directors. Each of Mr. Greenleaf and Mr. Howarth will receive a
- Zacks · Oct 7, 9:02 AM EDTCan NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.
- MarketBeat · Oct 1, 7:02 AM EDTAltimmune Details Pemvidutide’s Path Toward a Liver-Disease FranchiseMarketBeat Week in Review – 11/4 – 11/8Altimmune (NASDAQ:ALT) executives outlined the company’s strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic dysfunction-associated steatohepatitis, or MASH, alcohol use
- Zacks · Sep 11, 11:30 AM EDTWhy Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?Altimmune (ALT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks · Aug 19, 10:55 AM EDTIs Altimmune Worth Buying as Cash Rises but Execution Risks Linger?ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.
- Zacks · Aug 19, 10:54 AM EDTAltimmune's Phase III MASH Study Puts 2029 Data in Investor FocusALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.
- Zacks · Aug 14, 10:14 AM EDTKodiak's Q2 Loss Wider Than Expected, Pipeline Development in FocusKOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.
- Zacks · Aug 13, 12:14 PM EDTALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in FocusAltimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.
- RTTNews · Aug 13, 10:38 AM EDTAltimmune's Q2 Loss Widens Slightly Amid Headquarters Relocation To New Jersey(RTTNews) – Altimmune Inc. (ALT), a late clinical-stage biopharmaceutical company, on Wednesday announced financial results for the second quarter, noting a mild increase in loss owing to increased operating expenses.
- MarketBeat · Aug 12, 10:05 AM EDTAltimmune Q2 Earnings Call HighlightsMarketBeat Week in Review – 11/4 – 11/8Altimmune (NASDAQ:ALT) said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing plans for later-stage development in alcohol
- Zacks · Aug 12, 8:54 AM EDTBLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDABelite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Altimmune, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.